Perritt Capital Management Inc. trimmed its holdings in Rockwell Medical Inc (NASDAQ:RMTI) by 5.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 142,300 shares of the company’s stock after selling 8,750 shares during the period. Perritt Capital Management Inc. owned about 0.25% of Rockwell Medical worth $428,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Quantamental Technologies LLC grew its stake in Rockwell Medical by 194.3% in the first quarter. Quantamental Technologies LLC now owns 5,301 shares of the company’s stock valued at $30,000 after acquiring an additional 3,500 shares during the period. Greenleaf Trust acquired a new position in shares of Rockwell Medical during the second quarter worth about $36,000. Gabelli Funds LLC acquired a new position in shares of Rockwell Medical during the second quarter worth about $49,000. BNP Paribas Arbitrage SA boosted its position in shares of Rockwell Medical by 5,456.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,891 shares of the company’s stock worth $56,000 after buying an additional 9,713 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Rockwell Medical during the first quarter worth about $57,000. 25.32% of the stock is owned by hedge funds and other institutional investors.
RMTI traded down $0.08 on Thursday, hitting $2.91. 219,419 shares of the company were exchanged, compared to its average volume of 353,952. Rockwell Medical Inc has a 12 month low of $2.19 and a 12 month high of $6.88. The company has a market cap of $175.52 million, a PE ratio of -6.16 and a beta of 1.47. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.99 and a current ratio of 3.25. The stock’s fifty day moving average is $2.58 and its 200-day moving average is $4.03.
Several research analysts have recently weighed in on the company. ValuEngine raised Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cantor Fitzgerald assumed coverage on Rockwell Medical in a research report on Monday, June 24th. They set an “overweight” rating and a $11.00 price objective for the company. Ifs Securities cut Rockwell Medical from a “strong-buy” rating to an “outperform” rating in a research report on Wednesday, June 19th. HC Wainwright set a $12.00 price objective on Rockwell Medical and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Finally, Piper Jaffray Companies assumed coverage on Rockwell Medical in a research report on Monday, June 24th. They set an “overweight” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $9.65.
In other Rockwell Medical news, CFO Angus W. Smith acquired 10,000 shares of the company’s stock in a transaction on Friday, June 28th. The shares were purchased at an average price of $3.06 per share, for a total transaction of $30,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder David S. Richmond acquired 68,750 shares of the company’s stock in a transaction on Friday, July 19th. The stock was acquired at an average price of $2.89 per share, for a total transaction of $198,687.50. Following the purchase, the insider now directly owns 179,039 shares of the company’s stock, valued at $517,422.71. The disclosure for this purchase can be found here. Insiders have purchased 264,789 shares of company stock worth $779,198 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.
About Rockwell Medical
Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Read More: Why is the conference call important?
Want to see what other hedge funds are holding RMTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rockwell Medical Inc (NASDAQ:RMTI).
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.